Abstract
To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low‐density lipoprotein (LDL) cholesterol (LDL‐C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid‐lowering agents? Copyright © 2008 Wiley Periodicals, Inc.
Keywords: ENHANCE trial, ezetimibe, hypercholesterolemia
Full Text
The Full Text of this article is available as a PDF (77.8 KB).
References
- 1. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431–1443. [DOI] [PubMed] [Google Scholar]
- 2. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double‐blind trial. Lancet 2001; 357: 577–581. [DOI] [PubMed] [Google Scholar]
- 3. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, et al.: Effect of rosuvastatin on progression of carotid intima‐media thickness in low‐risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344–1353. [DOI] [PubMed] [Google Scholar]
- 4. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, et al.: Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high‐resolution magnetic resonance imaging trial. Am Heart J 2008; 155: 584.e1–584.e8. [DOI] [PubMed] [Google Scholar]
- 5. Ridker PM, JUPITER Study Group : Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low‐density lipoprotein cholesterol and elevated high‐sensitivity C‐reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292–2297. [DOI] [PubMed] [Google Scholar]
- 6. Clinical Trial . IMPROVE‐IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin. Available from http://www.clinicaltrials.gov/show /NCT 00202878 [Accessed 7 April 2008].
- 7. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–1592. [DOI] [PubMed] [Google Scholar]
- 8. Clinical Trial . AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Available from http://www.clinicaltrials.gov/show/NCT 00120289 [Accessed 7 April 2008].
- 9. Keech A, Simes RJ, Barter P, Best J, Scott R, et al.: Effects of long‐term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861. [DOI] [PubMed] [Google Scholar]
- 10. Clinical Trial . ACCORD: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Available from http://www.clinicaltrials.gov/show/NCT00000620 [Accessed 7 April 2008].